Skip to main content
Premium Trial:

Request an Annual Quote

Genomic Health, Pfizer Collaborate on Prognostic Renal Carcinoma Test

This article has been updated from a previous version, which incorrectly described the test as predictive instead of prognostic.
 
NEW YORK (GenomeWeb News) - Genomic Health said today it will work with Pfizer to develop a genomic test to estimate the risk of post-surgery recurrence of a carcinoma.
 
Genomic Health, working with Pfizer, will use the same technology it uses in its Oncotype Dx breast cancer recurrence test to create the prognostic test for patients with stage I-III renal carcinoma, clear cell type, if the disease has not spread to other parts of the body.
 
"Many early-stage renal carcinoma patients experience a recurrence of their cancer, yet there is no accurate way to identify the most aggressive cancers in advance,” Genomic Health’s VP of business development, Chu Chang, said in a statement.
 
"Working together with Pfizer, we have the potential to address a serious unmet need," Chang added.
 
Financial terms of the agreement were not provided.
 
News of the agreement gave Genomic Health shares a boost. In mid-afternoon trading, the company’s stock was up 6.16 percent, to $22.75.

The Scan

Study Links Genetic Risk for ADHD With Alzheimer's Disease

A higher polygenic risk score for attention-deficit/hyperactivity disorder is also linked to cognitive decline and Alzheimer's disease, a new study in Molecular Psychiatry finds.

Study Offers Insights Into Role of Structural Variants in Cancer

A new study in Nature using cell lines shows that structural variants can enable oncogene activation.

Computer Model Uses Genetics, Health Data to Predict Mental Disorders

A new model in JAMA Psychiatry finds combining genetic and health record data can predict a mental disorder diagnosis before one is made clinically.

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.